Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
5
×
biogen
5
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
5
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
5
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer immunotherapy
clinical trials
novartis
startups
alzheimer's disease
astrazeneca
bristol-myers squibb
cancer
deals
eli lilly
fda
What
bio
roundup
drug
acquisitions
biotech
ceo
news
albert
alzheimer’s
announced
annual
approval
assessed
attention
august
biggest
biogen’s
biopharmaceutical
bourla
busy
collabs
communities
companies
company
conference
convo
covid
crispr
daniel
days
deal
decisions
devices
drugs
earlier
esmo
europe
failures
fda
future
Language
unset
unknown
Current search:
biogen
×
abbvie
×
" raleigh-durham top stories "
×
" life sciences "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More